2023-2028 U.S. Virology, Bacteriology, Parasitology and Mycology Testing Market-Growth Opportunities, 2023 Supplier Shares by Test, 2023-2028 Centralized and POC Volume and Sales Forecasts for 100 Respiratory, STD, Enteric, and other Microbiology Assays Performed in Hospitals, Commercial/Private Labs, POC Volume and Sales Locations-Competitive Strategies and SWOT Analysis, Latest Technologies, Instrumentation Pipeline, Market Barriers and Risks

November 2023 | | ID: 245700CAA5C1EN
Venture Planning Group

Abstracts

This unique report from LeadingMarketResearch.com provides data and analysis not available from any other published source, including test volume and sales forecasts for 100 individual tests, and competitor strategies, as well as strategic analysis of major business opportunities emerging in the infectious disease testing market during the next five years.

The report is available by section, and can be customized to specific information needs and budget. The report examines key US market trends; reviews current and emerging assays; analyzes potential applications of innovative diagnostic technologies; forecasts volume and sales for over 100 infectious disease tests by assay, and market segment; provides test volume estimates by method (molecular, serology/immunodiagnostics, culture/microscopy); profiles leading players and potential market entrants; and suggests alternative business expansion strategies for suppliers.

Rationale
This comprehensive report will assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding microbiology testing market, in evaluating emerging opportunities and developing effective business strategies.

Microbiology testing is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers during this decade. Among the main driving forces is continuing spread of AIDS, which remains the world's major health threat and a key factor contributing to the rise of opportunistic infections; threat of bioterrorism; advances in molecular diagnostic technologies; and a wider availability of immunosuppressive drugs.

Although for some infections the etiology is still a mystery, while for others the causative microorganisms are present in minute concentrations long before the occurrence of first clinical symptoms, recent advances in genetic engineering and detection technologies are creating exciting opportunities for highly sensitive, specific and cost-effective products.

Opportunities and Strategic Recommendations

• Emerging opportunities for new instrumentation, reagents kits, IT and other products with significant market appeal during the next five years.
• Design criteria for decentralized testing products.
• Alternative market penetration strategies.
• Potential market entry barriers and risks.

Infectious Diseases Analyzed in the Report

AIDS/HIV, Adenovirus, Aeromonads, Bartonella, Blastocystis Hominis, Campylobacter, Candida, Carbapenemase, Chancroid, Chlamydia, Clostridium, Coronavirus, Coxsackievirus, Cryptosporidium, Cyclospora, CMV, E. Coli, Echovirus, Encephalitis, Enterovirus, EBV, Giardia, Gonorrhea, Granuloma Inguinale, Hantavirus, H. Pylori, Hepatitis, Herpes, Influenza, Legionella, Lyme Disease, Lymphogranuloma, Malaria, Measles, Meningitis, Microsporidium, Mononucleosis, Mumps, Mycoplasma, Norovirus, HPV, Parvovirus, Pneumonia, Polyomaviruses, Pseudomonas, Rabies, RSV, Rhinovirus, Rotavirus, Rubella, Salmonella, Septicemia, Shigella, Staphylococci, Streptococci, Syphilis, Toxoplasmosis, Trichomonas, TB, Vibrio, West Nile, Yersinia.

Market Segmentation Analysis

• Sales and market shares of major suppliers by individual test.
• Volume and sales forecasts for over 100 infectious disease assays by individual test and market segment:

Hospitals, Blood Banks, Commercial/Private Laboratories, Physicians Offices/Group Practices, Public Health Laboratories

• Test volume estimates by method (molecular, serology/immunodiagnostics, culture/microscopy).
• Review of the market dynamics, trends, structure, size, growth and major suppliers.

Current and Emerging Products

• In-depth examination of over 100 major diseases, including their etiology, current diagnostic tests, vaccines, drugs and market needs.
• Review of major analyzers used for infectious disease testing, including their operating characteristics, features and selling prices.

Technology Review

• Assessment of molecular diagnostic, monoclonal antibody, immunoassay, and other technologies and their potential applications for infectious disease testing.
• Global listings of companies developing or marketing infectious disease diagnostic products by individual test.

Competitive Assessments

Strategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborative arrangements and new products in R&D.

Contents

INTRODUCTION

WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

A. Major Infectious Disease Tests
  1. AIDS
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  2. Adenovirus
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
    d. Adeno-Associated Viruses(AAV)
  3. Aeromonas
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  4. Anthrax/Bacillus Anthracis
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  5. Arboviruses
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  6. Babesiosis
    a. Background
  7. Bacillary Epithelioid Angiomatosis (BEA) And Other
Bartonella (Rochalimaea)
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  8. Blastocystis Hominis
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  9. Brucella
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  10. Campylobacter
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  11. Candida
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  12. Chagas Disease
    a. Background
  13. Chancroid
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  14. Chlamydia
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  15. Clostridium Difficile
    a. Background
    b. Diagnostic Tests
    c. Drugs and Vaccines
  16. Coronaviruses
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  17. Coxsackieviruses
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  18. Creutzfeldt-Jakob’s Disease
    a. Background
    b. Diagnostic Tests
    c. Vaccines
  19. Cryptosporidium Parvum
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  20. Cyclospora Cayetanensis
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  21. Cytomegalovirus
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  22. Ebola Virus
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  23. E. Coli
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  24. EchoVirus
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  25. Encephalitis
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  26. Enteroviruses
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  27. Epstein-Barr Virus
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  28. Giardia Lamblia
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  29. Gonorrhea
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  30. Granuloma Inguinale
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  31. Hantavirus
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  32. Helicobacter Pylori
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  33. Hepatitis
    a. Background
    b. Hepatitis A
    c. Hepatitis B
    d. Hepatitis C
    e. Vaccines and Drugs
  34. Herpes Simplex Virus
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  35. Human Herpes Virus-6 (HHV-6)
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  36. Influenza Viruses
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  37. Legionella
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  38. Lyme Disease
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  39. Lymphogranuloma Venereum (LGV)
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  40. Malaria
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  41. Measles (Rubeola)
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  42. Meningitis
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  43. Microsporidium
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  44. Mononucleosis
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  45. Mumps
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  46. Mycoplasma
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  47. Papillomaviruses
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  48. Parvovirus B19
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  49. Pneumonia
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  50. Polyomaviruses
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  51. Pseudomonas Aeruginosa
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  52. Rabies
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  53. Respiratory Syncytial Virus (RSV)
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  54. RhinoViruses
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  55. RotaVirus (REOVIRUS)
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  56. Rubella(MEASLES)
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  57. Salmonellosis
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  58. Septicemia
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  59. Shigellosis
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  60. Staphylococcus Aureus
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  61. Streptococci
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  62. Syphilis
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  63. Toxoplasmosis
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  64. Trichomonas Vaginalis
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  65. Tuberculosis
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  66. Vibrio
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  67. West Nile Virus
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
  68. Yersina
    a. Background
    b. Diagnostic Tests
    c. Vaccines and Drugs
B. Instrumentation Review of Leading Analyzers Marketed by Abbott, Beckman Coulter/Danaher, BioMerieux, Ortho-Clinical Diagnostics, Roche, Siemens, Tosoh, Wallac and Other Suppliers
C. Emerging Diagnostic Technologies
  1. Molecular Diagnostics
  2. Monoclonal Antibodies
  3. Immunoassays
  4. Differential Light Scattering
  5. Information Technology
  6. Artificial Intelligence
  7. Liposomes
  8. Flow Cytometry
  9. Chromatography
  10. Diagnostic Imaging
  11. Gel Microdroplets
  12. Other

U.S.

A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth and Major Suppliers

MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

A. Instrumentation
B. Reagent Kits and Test Systems/Panels
C. Computers, Software and Automation
D. Auxiliary Products

DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

ALTERNATIVE MARKET PENETRATION STRATEGIES

A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized Testing Markets
  1. Marketing Approaches
  2. Product Complexity
  3. Customer Preference
  4. Established Suppliers
  5. Emerging Suppliers
  6. Major Types of Distributors
  7. Market Segmentation

POTENTIAL MARKET ENTRY BARRIERS AND RISKS

A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges

COMPETITIVE ASSESSMENTS

Abbott
Agilent Technologies
Applied Gene Technologies
Arca Biopharma
Beckman Coulter/Danaher
Becton Dickinson
Biokit
bioMerieux
Bio-Rad
Decode Genetics
Eiken Chemical
Elitech Group
Enzo Biochem
Exact Sciences
Fujifilm Wako
Fujirebio
Grifols
Hologic
Illumina
Leica Biosystems
Li-Cor Biosciences
Myriad Genetics
OrthoQuidel
PerkinElmer
Proteome Sciences
Qiagen
Quest Diagnostics
Roche
Scienion
Sequenom/LabCorp
Shimadzu
Siemens Healthineers
Sierra Molecular
Takara Bio
Tecan Group
Thermo Fisher